#### **LISTING OF THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of the claims in the application.

#### 1. (currently amended) A compound of general formula (1)

$$(R^2)_n \qquad \qquad \qquad R^3$$

$$P - R^1$$

wherein:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> may be same or different and are independently selected from the groups consisting of-hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heteroarylalkyl, -C(O)-R<sup>1</sup>, -C(O)O-R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>1</sup>, -S(O)<sub>m</sub>-R<sup>1</sup>, -S(O)<sub>m</sub>-NR<sup>1</sup>R<sup>1</sup>, nitro, -OH, cyano, amino, formyl, acetyl, halogen, -OR<sup>1</sup>, halogen, -OR<sup>1</sup>, -SR<sup>1</sup>, or a protecting groups group of and when two R<sup>2</sup> substitutents are ortho to each other, they may be joined to [[a]] form a saturated or unsaturated cyclic ring, which may optionally include up to two heteroatoms selected from O, NR<sup>1</sup> or S:

wherein P represents is an integer from 0-4;

Application No.: 10/532,273

Ar is substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, <u>a</u> substituted or unsubstituted heterocyclic ring or <u>a</u> substituted or unsubstituted heteroaryl ring;

X is oxygen, S(O)<sub>m</sub> or NR<sup>5</sup>;

R<sup>5</sup> represents <u>is</u> hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, -C(O)-R<sup>1</sup>, -C(O)O-R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>1</sup>, -S(O)<sub>m</sub>-R<sup>1</sup>, -S(O)<sub>m</sub>-NR<sup>1</sup>R<sup>1</sup>, nitro, -OH, cyano, amino, formyl, acetyl, halogen, -OR<sup>2</sup>, halogen, -OR<sup>2</sup>, -SR<sup>2</sup> or a and protecting groups group;

wherein m is 0, 1 or 2;

Y is  $-C(O)NR^4$ ,  $-NR^4SO_2$ ,  $-SO_2NR^4$  or  $-NR^4C(O)$ ;

R<sup>4</sup> is hydrogen, substituted or unsubstituted alkyl, hydroxyl, -OR<sup>1</sup>, -COOR<sup>1</sup>, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic ring[[;]],

and their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their N-oxides, or their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them or pharmaceutically acceptable salts or an analog, tautomer, regioisomer, stereoisomer, enantiomer, diastereomer, polymorph, pharmaceutically acceptable salt, N-oxide, or pharmaceutically acceptable solvate thereof.

2. (currently amended) A compound according to claim 1 wherein the substituents in the 'substituted alkyl', 'substituted alkoxy', 'substituted alkenyl', 'substituted alkynyl', 'substituted cycloalkyl', 'substituted cycloalkylalkyl', 'substituted cyclocalkenyl', 'substituted arylalkyl', 'substituted arylalkyl', 'substituted heterocyclic ring', 'substituted heteroaryl ring,' 'substituted heteroarylalkyl', 'substituted heterocyclylalkyl ring', 'substituted amino', 'substituted alkoxycarbonyl', 'substituted cyclic ring', 'substituted alkylcarbonyl', or 'substituted

alkylcarbonyloxy' and may be the same or different which and are one or more of selected from the groups such as hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio thio(=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, [[']]substituted heterocyclylalkyl ring[[']], substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted guanidine,  $-COOR^x$ ,  $-C(O)R^x$ ,  $-C(S)R^x$ ,  $-C(O)NR^xR^y$ ,  $-C(O)ONR^xR^y$ ,  $-NR^xCONR^yR^z$ ,  $-N(R^x)SOR^y$ , - $N(R^{x})SO_{2}R^{y}$ ,  $-(-N-N(R^{x})R^{y}) = N-N(R^{x})(R^{y})$ ,  $-NR^{x}C(O)OR^{y}$ ,  $-NR^{x}C(O)OR^{y}$ ,  $-NR^{x}R^{y}$ ,  $-NR^{x}C(O)R^{y}$ -.  $-NR^{x}C(S)R^{y}-NR^{x}C(S)NR^{y}R^{z}$ ,  $-SONR^{x}R^{y}-$ ,  $-SO_{2}NR^{x}R^{y}-$ ,  $-OR^{x}C(O)NR^{y}R^{z}$ ,  $-OR^{x}C(O)OR^{y}-$ ,  $-OR^{x}C(O)NR^{y}R^{z}$ ,  $-OR^{x}C(O)OR^{y}-$ ,  $-OR^{x}C(O)NR^{y}R^{z}$  $OC(O)R^x$ ,  $-OC(O)NR^xR^y$ ,  $-R^xNR^yC(O)R^z$ ,  $-R^xOR^y$ ,  $-R^xC(O)OR^y$ ,  $-R^xC(O)NR^yR^z$ ,  $-R^xC(O)R^x$ , R<sup>x</sup>OC(O)R<sup>y</sup>, -SR<sup>x</sup>, -SOR<sup>x</sup>, -SO<sub>2</sub>R<sup>x</sup>, or -ONO<sub>2</sub>, wherein R<sup>x</sup>, R<sup>y</sup> and R<sup>z</sup> in each of the above groups ean be are independently hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, [[']]substituted heterocyclylalkyl ring[[']] substituted or unsubstituted heteroarylalkyl, substituted or an unsubstituted heterocyclic ring[[,]].

- 3. (original) The compound according to claim 1 wherein R<sup>1</sup> is substituted alkyl.
- 4. (original) The compound according to claim 3 wherein  $\mathbb{R}^1$  is  $CHF_2$ .
- 5. (original) The compound according to claim 1 wherein R<sup>1</sup> is unsubstituted alkyl.
- 6. (original) The compound according to claim 5 wherein R<sup>1</sup> is methyl.

- 7. (currently amended) The compound according to <u>claim 1</u> elaims 1-5 or 6 wherein P is O or
- S.
- 8. (currently amended) The compound according to claim 7 where wherein P is O.
- 9. (currently amended) The compound according to <u>claim 1</u> elaims 1-7 or 8 wherein R<sup>2</sup> is seletted from the group consisting of substituted alkyl, halogen, cyano, nitro, amino, substituted heterocyclic <u>ring or and SO<sub>2</sub>NR<sup>1</sup>R<sup>1</sup></u> and n=1.
- 10. (original) The compound according to claim 9 wherein R<sup>2</sup> is chloro.
- 11. (original) The compound according to claim 9 wherein R<sup>2</sup> is substituted alkyl.
- 12. (original) The compound according to claim 11 wherein  $R^2$  is  $CF_3$ .
- 13. (original) The compound according to claim 9 wherein  $R^2$  is -NH<sub>2</sub>.
- 14. (currently amended) The compound according to claim 9 wherein  $R^2$  is  $-SO_2NR^1R^1$   $SO_2NR^1R^2$ .
- 15. (original) The compound according to claim 14 wherein  $R^2$  is  $SO_2N(CH_3)_2$ .
- 16. (currently amended) The compound according to <u>claim 1 claims 1-14 or 15</u> wherein Y is C(O)NH-.
- 17. (currently amended) The compound according to <u>claim 1</u> <u>claims 1-15 or 16</u> wherein Ar is <u>selected from the group consisting of</u> substituted or unsubstituted 4-pyridyl; substituted or unsubstituted 4-pyridyl-N-oxide; substituted or unsubstituted <u>3-pyridyl 3 pyridyl</u>, substituted or unsubstituted <u>3-pyridyl-N-oxide</u>; substituted or unsubstituted <u>2-pyridyl 2 pyridyl</u>; and or substituted or unsubstituted <u>2-pyridyl N-oxide</u>; <u>2-pyridyl N-oxide</u>.

18. (currently amended) The compound according to claim 17 wherein said substituent Ar is substituted with halogen.

7

- 19. (original) The compound according to claim 18 wherein said halogen is chloro.
- 20. (currently amended) The compound according to claim 17 wherein Ar is selected from the group consisting of

21. (original) The compound according to claim 20 wherein Ar is

Claims 22-59. (canceled)

60. (currently amended) A process for the preparation of <u>a compound</u> compounds of general formula (1)

$$(R^2)_n \xrightarrow{||} R^3$$

$$(1)$$

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> may be same or different and are independently selected from the groups eonsisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, -C(O)-R<sup>1</sup>, -C(O)O-R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>1</sup>, -S(O)<sub>m</sub>-R<sup>1</sup>, -S(O)<sub>m</sub>-NR<sup>1</sup>R<sup>1</sup>, nitro, -OH, cyano, amino, formyl, acetyl, halogen, OR<sup>4</sup> halogen, -OR<sup>1</sup>, -SR<sup>1</sup>, or a protecting group groups or and when two R<sup>2</sup> substitutents ortho to each other, they may be joined to a form a saturated or unsaturated cyclic ring, which may optionally include up to two heteroatoms selected from O, NR<sup>1</sup> or S;

wherein P represents is oxygen or sulfur;

wherein n represents is an integer from 0-4;

Ar is substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, a substituted or unsubstituted heterocyclic ring or a substituted or unsubstituted heterocyclic ring;

X is oxygen,  $S(O)_m$  or  $NR^5$ ;

R<sup>5</sup> is represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, -C(O)-R<sup>1</sup>, -C(O)O-R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>1</sup>, -S(O)<sub>m</sub>-R<sup>1</sup>, -S(O)<sub>m</sub>-NR<sup>1</sup>R<sup>1</sup>, nitro, -OH, cyano, amino, formyl, acetyl, halogen, OR<sup>2</sup> halogen, -OR<sup>2</sup>, -SR<sup>2</sup> and or a protecting groups group;

m is 0, 1 or 2;

Y is  $-SO_2NR^4$ ;

R<sup>4</sup> is hydrogen, substituted or unsubstituted alkyl, hydroxyl, -OR<sup>1</sup>, -COOR<sup>1</sup>, substituted or unsubstituted aryl, <u>or a</u> substituted or unsubstituted heterocyclic ring; comprising the steps of

## (a) chlorosulfonylation of the compound of general formula (26)

where the symbols are defined in the above with chlorosulfonic acid to get general formula (28)

(b)—reacting the compound of general formula (28) with an amine of the formula ArNHR<sup>4</sup> to get the novel compounds of formula (1)

$$(R^{2})_{n} \xrightarrow{X} R^{3}$$

$$28$$

$$(R^2)_n$$
  $R^3$   $R^1$   $R^3$   $R^3$   $R^4$   $R^3$   $R^3$   $R^4$   $R^3$   $R^3$   $R^4$   $R^3$   $R^3$   $R^3$   $R^4$   $R^3$   $R^3$   $R^3$ 

- [[(c)]] (b) optionally <u>converting</u> the <u>compound</u> empounds of formula 1 are converted into the corresponding N-oxide N-oxides by the action of a peracid.
- 61. (currently amended) A method for the preparation of <u>a compound</u> compounds of general formula (1)

$$(R^2)_n \xrightarrow{||} R^3$$

$$(1)$$

wherein:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> may be same or different and are independently selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heteroarylalkyl, -C(O)-R<sup>1</sup>, -C(O)O-R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>1</sup>, -S(O)<sub>m</sub>-R<sup>1</sup>, -S(O)<sub>m</sub>-NR<sup>1</sup>R<sup>1</sup>, nitro, -OH, cyano, amino, formyl, acetyl, halogen, -OR<sup>1</sup> halogen, -OR<sup>1</sup>, -SR<sup>1</sup>, or a protecting group groups or and when two R<sup>2</sup> substitutents are ortho to each other, they may be joined to a form a saturated or unsaturated cyclic ring, which may optionally include up to two heteroatoms selected from O, NR<sup>1</sup> or S;

wherein P represents is oxygen or sulfur;

wherein n represents is an integer from 0-4;

Ar is substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, <u>a</u> substituted or unsubstituted heterocyclic ring or <u>a</u> substituted or unsubstituted heteroaryl ring;

X is oxygen, S(O)<sub>m</sub> or NR<sup>5</sup>;

R<sup>5</sup> represents is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstitut

-OH, cyano, amino, formyl, acetyl, halogen, -OR<sup>2</sup> halogen, -OR<sup>2</sup>, -SR<sup>2</sup> and or a protecting group;

m is 0, 1 or 2;

Y is  $-C(O)NR^4$ ,  $-NR^4SO_2$ ,  $-SO_2NR^4$  or  $-NR^4C(O)$ ;

R<sup>4</sup> is hydrogen, substituted or unsubstituted alkyl, hydroxyl, -OR<sup>1</sup>, -COOR<sup>1</sup>, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic ring;

and their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their N oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them or a pharmaceutical acceptable salts thereof;

which comprises the steps of:

#### (a) nitrating the a compound of general formula (26)

$$\frac{(R^2)_n - R^3}{26}$$

where the symbols are defined in the above

to yield the nitro compounds of general formula (29)

(b) reacting the compound of general formula (29) with a reducing agent to yield an the amino compounds of general formula (30)

(c) reacting the amino compounds compound of general formula (30) with ArSO<sub>2</sub>Cl to yield a compound the compounds of general formula (31)

$$\frac{(R^2)_n - \frac{NHSO_2Ar}{R^3}}{X + \frac{1}{PR^1}}$$

(d) alkylating the a compound compounds of general formula (31)

$$(R^2)_n$$
 $X$ 
 $PR^1$ 
 $R^3$ 
 $R^3$ 

with an alkylating agent in the presence of a base to yield a compound the compounds of general formula (1)(1); and

$$(R^2)_n$$
 $NR^4SO_2Ar$ 
 $PR^1$ 
(1)
; and

- [[(e)]] (b) optionally converting the compound compounds of formula (1) into the corresponding N-oxide N-oxides by the action of a peracid.
- 62. (currently amended) A process for the preparation of <u>a compound</u> empounds of general formula (1)

$$(R^2)_n$$
 $R^3$ 
 $P-R^1$ 

(1)

wherein:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> may be same or different and are independently selected from the groups consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted eycloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted eycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, -C(O)-R<sup>1</sup>, -C(O)O-R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>1</sup>, -S(O)<sub>m</sub>-R<sup>1</sup>, -S(O)<sub>m</sub>-NR<sup>1</sup>R<sup>1</sup>, nitro, -OH, cyano, amino, formyl, acetyl, halogen,-OR<sup>1</sup>, -SR<sup>1</sup>, or a protecting group groups or and when two R<sup>2</sup> substitutents are ortho to each other, they may be joined to a form a saturated or unsaturated cyclic ring, which may optionally include up to two heteroatoms selected from O, NR<sup>1</sup> or S;

wherein P represents is oxygen or sulfur;

wherein n represents is an integer from 0 - 4;

Ar is substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, <u>a</u> substituted or unsubstituted heterocyclic ring or <u>a</u>substituted or unsubstituted heteroaryl ring;

X is oxygen,  $S(O)_m$  or  $NR^5$ ;

R<sup>5</sup> represents is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, -C(O)-R<sup>1</sup>, -C(O)O-R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>1</sup>, -S(O)<sub>m</sub>-R<sup>1</sup>, -S(O)<sub>m</sub>-NR<sup>1</sup>R<sup>1</sup>, nitro, -OH, cyano, amino, formyl, acetyl, halogen,-OR<sup>2</sup>, -SR<sup>2</sup> and or a protecting groups group;

m is 0, 1 or 2;

Y is  $-NR^4C(O)$ ;

R<sup>4</sup> is hydrogen, substituted or unsubstituted alkyl, hydroxyl, -OR<sup>1</sup>, -COOR<sup>1</sup>, substituted or unsubstituted aryl, <u>or a</u> substituted or unsubstituted heterocyclic ring;

and their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their N oxides, their

pharmaceutically acceptable solvates and their pharmaceutical compositions containing them or a pharmaceutical acceptable salts thereof;

which comprises the steps of;

(a) nitrating the compound of general formula (26)

$$\frac{(R^2)_n - \frac{1}{26} R^3}{26}$$

to yield the nitro compounds of general formula (29)

(b) reacting the compound of general formula (29) with a reducing agent to yield the amino compounds of general formula (30)

(c) reacting the amino compounds of general formula (30) with ArCOCl or a mixed anhydride of the formula ArCOOCOR<sup>5</sup> where R<sup>5</sup> substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocyclic ring, heteroaryl, to yield the compounds of general formula (32)

$$\begin{array}{c|c}
(R^2)_n & & & \\
\hline
(R^2)_n & & & \\
\hline
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\$$

(d) alkylating a compound the compounds of general formula (32)

$$(R^2)_n$$
 $X$ 
 $PR^1$ 
 $R^3$ 
 $R^3$ 

Application No.: 10/532,273

15

with an alkylating agent to yield the compounds a compound of general formula (1)(1)


$$(R^2)_n$$
 $(R^2)_n$ 
 $(R^3)_n$ 
 $(R^3)_n$ 

- [[(e)]] (b) optionally converting the <u>compound compounds</u> of formula (1) into the corresponding N-oxides by the action of a peracid N-oxide.
- 63. (currently amended) A pharmaceutical composition comprising <u>one or more compounds</u> a <u>compound</u> according to <u>claims 1-51 or 52 claim 1</u> and pharmaceutically acceptable salts or solvates thereof <u>as well as</u> and <u>one or more pharmaceutically acceptable diluents or carriers.</u>
- 64. (canceled)
- 65. (currently amended) A method of treating <u>an</u> inflammatory <del>condition</del> <del>conditions and <u>or</u></del> immune <u>disorder</u> disorders in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound according to claim 1 <del>claims 1 51 or 52</del>.
- 66. (currently amended) The method according to claim 65 wherein said inflammatory condition or conditions and immune disorder disorders is chosen from the group consisting of asthma, bronchial asthma chronic obstructive pulmonary disease, allergic rhinitis, eosinophilic granuloma, nephritis, rheumatoid arthritis, cystic fibrosis, chronic bronchitis, multiple sclerosis, Crohns disease, psoraisis, uticaria, adult vernal cojunctivitis, respiratory distress syndrome, rhematoid spondylitis, osteoarthritis, gouty arthritis, <u>uveitis uteltis</u>, allergic conjunctivitis, inflammatory bowel conditions, ulcerative coalitis, eczema, atopic dermatitis <u>or and</u> chronic inflammation.
- 67. (original) The method according to claim 66 wherein said inflammatory condition is an allergic inflammatory condition.

68. (currently amended) The method according to claim 67 wherein said inflammatory condition or conditions and immune disorder is an disorders are selected from the group consisting of inflammatory condition—conditions or immune disorder disorders of the lungs, joints, eyes, bowels, skin or and heart.

- 69. (currently amended) The method according to claim 68 wherein whrein said inflammatory condition is chosen from the group consisting of bronchial asthma, nepritis, or and allergic rhinitis.
- 70. (currently amended) A method for abating inflammation in an affected organ or tissue comprising delivering to said organ or tissue a therapeutically effective amount of a compound represented by a compound according to claim 1-claims 1-51 or 52.
- 71. (currently amended) A method of treating <u>a disease</u> diseases of the central nervous system in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound according to <u>claim 1 elaims 1-51 or 52</u>.
- 72. (currently amended) The method according to claim 71 wherein said <u>disease</u> diseases of the central nervous system <u>is</u> are chosen from the group consisting of depression, amnesia, dementia, Alzheimers disease, cardiac failure, shock <u>or and</u> cerebrovascular disease.
- 73. (currently amended) A method of treating insulin resistant diabetes in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound according to claim 1 elaims 1-51 or 52.

## 74. (New) A method for the preparation of a compound of general formula (1)



wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> may be same or different and are hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkyl, -C(O)-R<sup>1</sup>, -C(O)O-R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>1</sup>, -S(O)<sub>m</sub>-R<sup>1</sup>, -S(O)<sub>m</sub>-NR<sup>1</sup>R<sup>1</sup>, nitro, -OH, cyano, amino, formyl, acetyl, halogen, -OR<sup>1</sup>, -SR<sup>1</sup>, a protecting group and when two R<sup>2</sup> substitutents ortho to each other, they may be joined to a form a saturated or unsaturated cyclic ring, which may optionally include up to two heteroatoms selected from O, NR<sup>1</sup> or S;

P is oxygen or sulfur;

n is an integer from 0-4;

Ar is substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring or substituted or unsubstituted heterocyclic ring;

X is oxygen, S(O)<sub>m</sub> or NR<sup>5</sup>;

R<sup>5</sup> represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted or unsubstituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heterocyclylalkyl, -C(O)-R<sup>1</sup>, -C(O)O-R<sup>1</sup>, -C(O)NR<sup>1</sup>R<sup>1</sup>, -S(O)<sub>m</sub>-R<sup>1</sup>, -S(O)<sub>m</sub>-NR<sup>1</sup>R<sup>1</sup>, nitro, -OH, cyano, amino, formyl, acetyl, halogen, -OR<sup>2</sup>, -SR<sup>2</sup> or a protecting group;

Application No.: 10/532,273

18

m is 0, 1 or 2;

Y is  $-C(O)NR^4$ ;

R<sup>4</sup> is hydrogen, substituted or unsubstituted alkyl, hydroxyl, -OR<sup>1</sup>, -COOR<sup>1</sup>, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic ring,

or an N-oxide thereof;

comprising the steps of:

(a) reacting the compound of formula (11):

$$(R^2)_n$$
 $X$ 
 $PR^1$ 
 $R^3$ 

with an amine of the formula ArNHR<sup>4</sup> to yeild a compound of formula (1)

$$(R^2)_n$$
  $(R^3)_n$   $(R^3$ 

- (b) optionally converting the compound of formula (1) into its corresponding N-oxide.
- 75. (New) The method of claim 74 wherein the compound of formula (11) is formed by
- (a) converting the compound of general formula (10)

$$(R^2)_n$$
 $PR^1$ 

to general formula (11) wherein FG represents substituted or unsubstituted alkyl, formyl, cyano, halogen, nitro, amino or a carboxylic acid group.

- 76. (New) The method of claim 75 wherein the compound of formula (10) is prepared by:
- (i) reacting a compound of formula (13.a) with a compound of formula (23) under basic conditions

wherein Z is a halogen; FG is a substituted or unsubstituted alkyl, formyl, cyano, halogen, nitro, or amino; and Hal is halogen, to yield a compound of formula (24)

$$(R^2)_n \xrightarrow{\text{Hal}} X \xrightarrow{\text{PR}^1} R^3$$

- (ii) cyclizing the compound of general formula (24) under palladium catalyzed coupling conditions to form a tricyclic compound of general formula (10).
- 77. (New) The method of claim 75 wherein the compound of formula (10) is prepared by:
- (i) reacting a compound of general formula (25) with an electrophile

wherein FG is alkyl, formyl, cyano, halogen, nitro, or amino; to yield a compound of formula (10).

- 78. (New) The method of claim 75 wherein the compound of formula (10) is formed by:
- (i) reacting a compound-of general-formula (13) with a compound of formula (20) under basic conditions

$$HX \xrightarrow{PR^1}^{FG} R^3$$

to yield a compound of general formula (21)

wherein FG is alkyl, formyl, cyano, halogen, nitro, or amino; and Z is a halogen; and

- (ii) cyclizing the compound of general formula (21) under acidic conditions followed by oxidation to yield a tricyclic compound of general formula (10).
- 79. (New) The method of claim 75 wherein the compound of formula (10) is formed by:
- (i) reacting a compound of formula (16) with a compound of formula (17)

where A is halogen, -OMs, -OTs or  $-B(OH)_2$ ; Ms is a methanesulfonyl group; Ts is a p-toluenesulfonyl group;  $B_1$  is halogen; G is a protecting group selected from benzyloxycarbonyl, t-butyloxycarbonyl, isopropyl, cyclopentyl, allyl, acetyl and benzyl, FG is alkyl, formyl, cyano, halogen, nitro, or amino; and Z is halogen;

to yield a compound of formula (18)

(ii) deprotecting the compound of formula (18) to yield a compound of formula (19)

21

$$(R^2)_n$$
 $\xrightarrow{B_1}$ 
 $\xrightarrow{HX}$ 
 $\xrightarrow{PR^1}$ 
; and

- (iii) cyclizing the intermediate of formula (19) under basic conditions to yield a tricyclic compound of formula (10).
- 80. (New) The method of claim 75 wherein the compound of formula (10) is prepared by:
- (i) reacting a compound of general formula (12) where Z is a halogen

$$(R^2)_n$$
 $V$ 
 $Z$ 
 $Z$ 

with an aromatic group of formula (13)

wherein FG is alkyl, formyl, cyano, halogen, nitro, or amino, under basic conditions to yield a compound of formula (14)

$$(R^2)_n \xrightarrow{NO_2} \overset{FG}{\underset{PR^1}{\bigvee}} R^3$$

(ii) reducing the compound of formula (14) to obtain a compound of formula (15)

- (iii) cyclizing of the compound of formula (15) to yield a tricyclic compound of formula (10).
- 81. (New) The method of claim 75, wherein (i) FG is methyl and step (a) comprises oxidizing the compound of formula (10) with a manganese or chromium reagent to form a compound of

Application No.: 10/532,273

22

formula (11), (ii) FG is cyano and step (a) comprises hydrolyzing the compound of formula (10) to form a compound of formula (11), or (iii) FG is bromine and step (a) comprises reacting the compound of formula (10) with lithium followed by treatment with carbon dioxide to form a compound of formula (11).

- 82. (New) The method of claim 74 wherein the compound of formula (11) is prepared by:
- (a) formylation of a compound of formula (26)

followed by oxidation of the aldehyde group in the resulting compound of formula (27)

83. (New) The method of claim 60, wherein the compound of formula (28) is formed by chlorosulfonylation of the compound of formula (26)

$$(R^2)_n \xrightarrow{\qquad \qquad \qquad } R^3$$

$$26$$

84. (New) The method of claim 61, wherein the compound of formula (31) is prepared by (a) nitrating a compound of formula (26)

$$(R^2)_n \xrightarrow{\qquad \qquad \qquad } R^3$$

$$26$$

to yield a nitro compound of formula (29)

$$(R^2)_n$$
  $X$   $PR^1$   $R^3$ 

(b) reacting the compound of formula (29) with a reducing agent to yield an amino compound of general formula (30)

$$(R^2)_n \xrightarrow{\parallel} X \xrightarrow{\parallel} R^3$$

$$30$$

(c) reacting the amino compound of formula (30) with ArSO<sub>2</sub>Cl to yield a compound of formula (31)

$$(R^2)_n$$
 $(R^2)_n$ 
 $(R^3)_n$ 
 $(R^3)_n$ 
 $(R^3)_n$ 
 $(R^3)_n$ 

- 85. (New) The method of claim 62, wherein the compound of Formula (32) is prepared by:
- (a) nitrating a compound of formula (26)

$$(R^2)_n \xrightarrow{\qquad \qquad \qquad } R^3$$

to yield a nitro compound of formula (29)

$$(R^2)_n \xrightarrow{\qquad \qquad \qquad } R^3$$

$$29$$

(b) reacting the compound of formula (29) with a reducing agent to yield an amino compound of formula (30)

$$(R^2)_n \xrightarrow{X^1} R^3$$

$$30$$

(c) reacting the amino compound of formula (30) with ArCOCl or a mixed anhydride of the formula ArCOOCOR<sup>5</sup> where R<sup>5</sup> is a substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocyclic ring, heteroaryl, to yield a compound of formula (32)

$$(R^2)_n$$
 $X$ 
 $PR^1$ 
 $R^3$ 

86. (New) A compound selected from

N-(3, 5-dichloropyrid-4-yl)-4-methoxy dibenzo[b,d]furan-1-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-methoxy dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-nitro dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-amino-dibenzo[b,d]furan-1-carboxamide, or a pharmaceutically acceptable salt thereof.

- 87. (New) A compound selected from
- N-(3, 5-dichloropyrid-4-yl)-4-difluoromethoxy dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide-N-oxide, or a pharmaceutically acceptable salt thereof.

88. (New) A compound selected from

N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-nitro-dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-amino-dibenzo[b,d]furan-1-carboxamide, or a pharmaceutically acceptable salt thereof.

89. (New) A compound selected from

N-(3, 5-dichloropyrid-4-yl)-4-isopropyloxy dibenzo[b,d]furan-1-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-cyclopropylmethoxy dibenzo[b,d]furan-1-carboxamide N-(3, 5-dichloropyrid-4-yl)-4-benzyloxy dibenzo[b,d]furan-1-carboxamide, or a pharmaceutically acceptable salt thereof.

90. (New) A compound of claim 1 selected from

N-(pyrid-4-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(2-chloropyrid-3-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

N-(4-fluorophenyl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(3, 5-dichloropyrid-4-yl)-4-methoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-methoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-4-yl)-4-methoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide-N1-oxide.

N-(pyrid-4-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-3-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-2-yl)-4-difluoromethoxy-8-trifluoromethyl dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-3-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(5-chloropyrid-2-yl)-4-difluoromethoxy-dibenzo[b,d]furan-1-carboxamide, or a pharmaceutically acceptable salt thereof.

Docket No.: 04654/0200039-US0

## 91. (New) A compound of claim 1 selected from

N-(3, 5-dichloropyrid-4-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-4-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-3-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-cyclopropylmethoxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(3, 5-dichloropyrid-4-yl)-4-hydroxycarbomethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-4-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-3-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide.

N-(pyrid-3-yl)-4-isopropyloxy-dibenzo[b,d]furan-1-carboxamide-N1-oxide,

N-(pyrid-4-yl)-4-methoxy-8-nitro dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-8-nitro dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-chloro-dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-bromo-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-methoxy-8-bromo-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-8-bromo-dibenzo[b,d]furan-1-carboxamide,

N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-iodo-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-4-yl)-4-methoxy-8-iodo-dibenzo[b,d]furan-1-carboxamide,

N-(pyrid-3-yl)-4-methoxy-8-iodo-dibenzo[b,d]furan-1-carboxamide,

N-(4-methylpyrimid-2-yl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide,

N-(2,5-dichlorophenyl)-4-methoxy-dibenzo[b,d]furan-1-carboxamide, or

a pharmaceutically acceptable salt thereof.

## 92. (New) A compound of claim 1 selected from

N-(3, 5-dichloropyrid-4-yl)-4-ethoxycarbomethoxy-dibenzo[b,d]furan-1-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-methoxy-dibenzo[b,d]furan-2-carboxamide,

N-(3, 5-dichloropyrid-4-yl)-4-methoxy-dibenzo[b,d]furan-3-carboxamide.

- N4-(4-methoxy-dibenzo[b,d]furan-1-yl) isonicotinamide,
- N-(3, 5-dichloropyrid-4-yl)-4-methoxy-dibenzo[b,d]furan-1-sulfonamide,
- N-(3,5-dichloropyrid-4-yl)-4-methoxy-8-cyano-dibenzo[b,d]furan-1-carboxamide,
- 3,5-Dichloro-4-(4-ethoxydibenzo[b,d]furan-1-ylcarboxamido)pyridine,
- N1-Benzyl-4-cyclopentyloxydibenzo[b,d]furan-1-carboxamide,
- 4-(4-Cyclopentyloxydibenzo[b,d]furan-1-ylcarboxamido)pyridine,
- 3,5-Dichloro-4-(4-cyclopentyloxydibenzo[b,d]furan-1-ylcarboxamido)pyridine,
- 4-(4-Methylsulfanyldibenzo[b,d]furan-1-ylcarboxamido)pyridine,
- N3-(4-Methoxydibenzo[b,d]furan-1-yl)nicotinamide,
- N1-Benzyl-4-methoxydibenzo[b,d] furan-1-sulfonamide,
- 4-(4-Methoxydibenzo[b,d]furan-1-ylsulfonamido)pyridine,
- 3,5-Dichloro-4-(4-ethoxydibenzo[b,d]furan-1-ylcarboxamido)pyridine-N-oxide,
- 3,5-Dichloro-4-(4-cyclopentyloxydibenzo[b,d]furan-1-ylcarboxamido)pyridine-N-oxide,
- N-Formyl-1-methoxy-4-[4-methoxyphenylaminosulphonyl]-9H-carbazole,
- 1-methoxy-4-[4-methoxyphenylaminosulphonyl]-9H-carbazole,
- N-Formyl-1-methoxy-4-[4-methylphenylaminosulphonyl]-9H-carbazole,
- 1-methoxy-4-[4-methylphenylaminosulphonyl]-9H-carbazole,
- 1-methoxy-4-[4-methylphenylaminosulphonyl-N'-methyl]-9H-carbazole,
- 1-methoxy-4-[4-methylphenylaminosulphonyl-N'-methyl]-9methyl carbazole,
- 1-methoxy-4-[4-pyridinylaminosulphonyl]-9H-carbazole, or
- a pharmaceutically acceptable salt thereof.
- 93. (New) A compound of claim 1 selected from
- N4-(2,6-Dichlorophenyl)-1-methoxy-9H-4-carbazolsulphonamide,
- N4-(2,6-Dichlorophenyl)-9-formyl-1-methoxy-9H-4-carbazolsulphonamide,
- N4-(4-pyridyl)-1-methoxy-9H-4-carbazole carboxamide.
- N4-(3,5-dichloro-4-pridyl)-1-methoxy-9H-4-carbazole carboxamide,
- N4-(3, 5-dichloro-4-pyridyl) -6-chloro-1-methoxy-9H-4-carbazole carboxamide,
- N4-(3, 5-dichloro-4-pyridyl) -9-benzyl -6-chloro-1-methoxy-9H-4-carbazole carboxamide,

N4-(3, 5-dichloro-4-pyridyl) -6-chloro-9-cyclohexylmethyl -1-methoxy-9H-4-carbazole carboxamide,

N4-(3, 5-dichloro-4-pyridyl) -6-chloro-9-(4-fluorobenzyl)-1-methoxy-9H-4-carbazole carboxamide,

N4-(3, 5-dichloro-4-pyridyl) -6-chloro-9-(4-methoxybenzyl)-1-methoxy-9H-4-carbazolecarboxamide,

N4-(3, 5-dichloro-4-pyridyl)-9-(4-fluorobenzyl)-1-methoxy-9H- 4-carbazole carboxamide,

N4-(4-pyridyl)-9-(4-fluorobenzyl)-1-methoxy -9H-4-carbazole carboxamide,

N4-(3, 5-dichloro-4-pyridyl)-9-benzyl-1-methoxy-9H-4-carbazolecarboxamide,

N4-(3, 5-dichloro-4-pyridyl)-9-benzyl-1-ethoxy-9H-4-carbazolecarboxamide,

N4-(3, 5-dichloro-4-pyridyl)-9-benzyl-6-chloro-1-ethoxy-9H-4-carbazolecarboxamide,

N4-(4-pyridyl)-9-benzyl-1-ethoxy-9H-4-carbazolecarboxamide,

N4-(3-pyridyl)-6-chloro-9-(4-fluorobenzyl)-1-methoxy-9H-4-carbazolecarboxamide,

N4-(4-pyridyl)-6-chloro-9-(4-fluorobenzyl)-1-methoxy-9H-4-carbazolecarboxamide,

N4-(3, 5-dichloro-4-pyridyl) 8-chloro-9-cyclohexylmethyl-1-methoxy-9H-4-carbazole carboxamide,

N4-(3, 5-dichloro-4-pyridyl)- 8-chloro-9-(4-Fluorobenzyl)-1-methoxy-9H- 4-carbazole carboxamide,

N4-(3, 5-dichloro-4-pyridyl)-6-chloro-1-methoxy-9-methyl-9H-4-carbazole carboxamide,

N4-(3,5-dichloro-4-pyridyl-N-oxide)-6-chloro-9-(4-fluorobenzyl)-1-methoxy-9H-4-carbazolecarboxamide,

N4-(3,5-dichloro-4-pyridyl-N-oxide)-6-chloro-9-(4-methoxybenzyl)-1-methoxy-9H-4-carba-zolecarboxamide, or

a pharmaceutically acceptable salt thereof.

# 94. (New) A compound of claim 1 selected from

N4-(3,5-dichloro-4-pyridyl-N-oxide)-6-chloro-9-cyclohexylmethyl-1-methoxy-9H-4-carbazolecarboxamide,

N4-(3, 5-dichloro-4-pyridyl)-9-methyl -1-methoxy-9H-4-carbazolecarboxamide,

3,5-Dichloro-4-(4-methoxydibenzo[b,d]-thiophen-1- ylcarboxamido)pyridine,

- 3,5-Dichloro-4-(4-cyclopentyloxydibenzo[b,d]-thiophen-1-ylcarboxamido)pyridine,
- N1 (4-methoxyphenyl)-4-methoxydibenzo[b,d]thiophene-1-carboxamide,
- N1-(4-methoxyphenyl)-4-methoxydibenzo[b,d]thiophene-1-carboxamide-5,5-dioxide,
- N1-(4-chlorophenyl)-4-methoxydibenzo[b,d]thiophene-1-carboxamide,
- 4-(4-methoxydibenzo[b, d]thiophene-1-ylcarboxamido)pyridine,
- 4-(4-Cyclopentyloxydibenzo[b,d]thiophene-1-yl-carboxamido)pyridine,
- 3,5-Dichloro-4-(4-cyclopentyloxydibenzo[b,d]-thiophen-5,5-dioxide-1-ylcarbox-amido)pyridine-Noxide,
- 3,5-Dichloro-4-(4-methoxydibenzo[b,d]-thiophen-5,5-dioxide-1-yl-carboxamido) pyridine-N-oxide,
- 3,5Dichloro-4-(4-methoxydibenzo[b,d]-thiophen-5,5-dioxide-1-yl-carboxamido) pyridine,
- 3.5 Dichloro-4-(4-difluoromethoxydibenzo[b,d]-thiophen-1-ylcarboxamido) pyridine,
- N1-(4-methoxyphenyl)-4-methoxydibenzo [b,d]thiophene-1-sulfonamide,
- 2-(4-Methoxydibenzo[b,d] thiophen-1-ylcarboxamido)-pyridine,
- 4-(4-Ethoxydibenzo[b,d] thiophen-1-yl-carboxamido)-pyridine,
- N1-(4-methoxyphenyl)-8,N8-dimethyl-4-methoxydibenzo[b,d]thiophen-8,1-disulfo-amide,
- 3-(4-Methoxydibenzo[b,d] thiophen-1-ylcarboxamido)-pyridine,
- 3,5-Dichloro-4-(6-ethyl-4-methoxydibenzo[b,d]-thiophen-1- ylcarboxamido)pyridine,
- 3,5,dichloro-4-(4-ethoxy-dibenzo[b, d]thiophen-1-yl-carboxamido)pyridine,
- 3-(4-Methoxydibenzo[b,d]-thiophene-5,5-dioxide-1-ylcarboxamido)-pyridine,
- 3,5-Dichloro-4-(4-benzyloxydibenzo[b,d]-thiophen-1- ylcarboxamido)pyridine,
- N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-(pyrrolidine-2-one-1-yl)-dibenzo[b,d]furan-1-carboxamide, or
- a pharmaceutically acceptable salt thereof.
- 95. (New) A compound selected from

$$O_2N$$
 $O_2N$ 
 $O_2N$ 
 $O_2N$ 
 $O_3N$ 

$$O_2N$$
  $O_2N$   $O_2N$